O.10 Cardiotoxicity of immune checkpoint inhibitors (ICI): a systematic review and meta-analysis of randomized clinical trials

BJMO - 2021, issue 3, march 2021

Elisa Agostinetto , Daniel Eiger , Matteo Lambertini , Marcello Ceppi , Marco Bruzzone , Noam Ponde , Chris Plummer , Ahmad Hussein Awada , Martine Piccart-Gebhart , Evandro de Azambuja

Introduction: ICI can cause potentially life-threatening adverse events (AE) and their risk of cardiotoxicity has been poorly investigated. It is also unknown whether ICI combinations increases cardiotoxicity compared to single ICI. We aimed to assess the cardiotoxicity rate of ICI compared to other cancer treatments (primary objective) and of dual-agent ICI (immunotherapy combinations) compared to single-agent ICI (secondary objective).

Read more